Investment News · 24 October 2026 · 2 min read
In short: Dr Reddy’s Laboratories reported a net profit of ₹925 crore for July to September 2026, 36% lower than a year ago. Revenue slipped 1.5% to ₹8,671 crore. The main reason: falling US sales of lenalidomide, a generic version of the blood-cancer drug Revlimid that had been a big earner.
Key numbers
| Jul–Sep 2026 | Change | |
|---|---|---|
| Net profit | ₹925 crore | −36% vs last year; more than double last quarter |
| Revenue | ₹8,671 crore | −1.5% vs last year; +7.4% vs last quarter |
| North America sales | ₹2,489 crore | −23% |
| India sales | – | +17% |
| Emerging markets sales | – | +24% |
| EBITDA margin | 20.6% | – |
What to know
- Losing a star product: as more companies sell cheap versions of lenalidomide in the US, prices and sales fall. Leaving it out, Dr Reddy’s says its US business grew 12%.
- Strong at home: it is now India’s 8th-largest drug maker by sales, up from 10th a year ago.
- Weight-loss drug relaunch: it expects to relaunch semaglutide, the medicine in Ozempic, in November after fixing supply problems that hurt the last quarter.
- War costs: the West Asia conflict raised raw material and freight costs, cutting margins by about 1 percentage point.
Sources
- Business Standard: Dr Reddy’s Q2 profit falls 36% (23 October 2026)
- Kotak Neo: Dr Reddy’s Q2 FY27 results
This is a news summary for education, not investment advice. Figures are as reported on or before 24 October 2026; check official filings before making decisions.